scispace - formally typeset
Y

Yang Lu

Researcher at Huazhong University of Science and Technology

Publications -  5
Citations -  556

Yang Lu is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: Internal medicine & DLCO. The author has an hindex of 3, co-authored 4 publications receiving 164 citations.

Papers
More filters
Journal ArticleDOI

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study.

TL;DR: In this paper, the authors describe the temporal trends in respiratory outcomes over 12 months in patients hospitalised for severe COVID-19 and investigate the associated risk factors, including a history of hypertension, diabetes, cardiovascular disease, cancer, and chronic lung disease, including asthma or chronic obstructive pulmonary disease.
Journal ArticleDOI

Risk factors associated with disease severity and length of hospital stay in COVID-19 patients.

TL;DR: Department of Pulmonary and Critical Care Medicine, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhian, Hubei, China; Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton SO17 1BJ, UK.
Journal ArticleDOI

Temporal radiographic changes in COVID-19 patients: relationship to disease severity and viral clearance.

TL;DR: Log-rank test and Spearman's Rank-Order correlation suggested temporal radiographic changes as a valuable predictor for viral clearance in COVID-19 patients with severe pneumonia, and follow up CT scans from 11 pneumonia patients showed full recovery.
Journal ArticleDOI

Different Laboratory Abnormalities in COVID-19 Patients with Hypertension or Diabetes.

TL;DR: Renin–angiotensin–aldosterone system inhibitors and risk of covid-19, clinical characteristics of coronavirus disease 2019 in China, and risk factors associated with disease severity and length of hospital stay.
Journal ArticleDOI

Camrelizumab plus chemotherapy in advanced non‐squamous non‐small cell lung cancer: Treatment response, survival pattern, and safety

TL;DR: Camrelizumab plus chemotherapy exhibits good efficacy and manageable adverse events in treating advanced non-squamous NSCLC patients and most adverse events were controllable.